The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …

Recent studies on pediatric acute myeloid leukemia (pAML) have revealed pediatric-specific
driver alterations, many of which are underrepresented in the current classification schemas …

Diagnostic karyotype provides the framework for risk-stratification schemes in acute myeloid
leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic …

Despite major improvements in outcome over the past decades, acute myeloid leukemia
(AML) remains a life-threatening malignancy in children, with current survival rates of∼ …

Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …

The genetics of relapsed pediatric acute myeloid leukemia (AML) has yet to be
comprehensively defined. Here, we present the spectrum of genomic alterations in 136 …

Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …

PURPOSE We investigated the impact of the CD33-targeted agent gemtuzumab ozogamicin
(GO) on survival in pediatric patients with KMT2A-rearranged (KMT2A-r) acute myeloid …

Pediatric acute myeloid leukemia is a rare and heterogeneous disease in relation to
morphology, immunophenotyping, germline and somatic cytogenetic and genetic …